AMPH Q3 2018 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$76M+30.4% YoY

Gross Profit

$29M38.7% margin

Operating Income

$3M3.4% margin

Net Income

$2M3.2% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

+6.3%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$481M

Total Liabilities

$139M

Stockholders' Equity

$319M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$58M	+30.4%
Gross Profit	$29M	$21M	+41.8%
Operating Income	$3M	-$3M	+190.4%
Net Income	$2M	$175,000	+1265.1%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$4M100%

Geographic Segments

U

$72M100%